IP Library Granted Patent US 11,548,890
Granted Patent B1
US 11,548,890 · App. 17/305,632 · Granted Jan 10, 2023

HPK1 antagonists and uses thereof

Inventors: Neelu Kaila (Lexington, MA); Ian Linney (Saffron Walden, GB); Stuart Ward (Saffron Walden, GB); Grant Wishart (Saffron Walden, GB); Ben Whittaker (Saffron Walden, GB); Alexandre Cote (West New York, NJ); Jeremy Robert Greenwood (Brooklyn, NY); Abba Leffler (Bronx, NY); Steven K. Albanese (Brooklyn, NY); Daniel L. Severance (San Diego, CA)
Assignee: Nimbus Saturn, Inc.
C07D471/04C07D401/14C07D487/04C07D495/04C07D498/04C07D519/00C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,548,890
App. No.
17/305,632
Granted
Jan 10, 2023
Kind
B1
Abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

Claims (60)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

25. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

27. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

28. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

29. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

30. The pharmaceutical composition of claim 12 , wherein said compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Assignments (15)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: CHARLES RIVER LABORATORIES, INC.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 058575/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: LEFFLER, ABBA
To: SCHRÖDINGER, INC.
Reel/Frame 058577/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: ALBANESE, STEVEN K.
To: SCHRÖDINGER, INC.
Reel/Frame 058577/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: SCHRÖDINGER, INC.
To: SCHRÖDINGER, L.L.C.
Reel/Frame 058578/0023 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: GREENWOOD, JEREMY ROBERT
To: SCHRÖDINGER, INC.
Reel/Frame 058579/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: SEVERANCE, DANIEL L.
To: SCHRÖDINGER, INC.
Reel/Frame 058580/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: SCHRÖDINGER, L.L.C.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 058581/0797 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: KAILA, NEELU
To: NIMBUS DISCOVERY, INC.
Reel/Frame 058584/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: WHITTAKER, BEN
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 058584/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: NIMBUS DISCOVERY, INC.
To: NIMBUS SATURN, INC.
Reel/Frame 058585/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: COTE, ALEXANDRE
To: SCHRÖDINGER, INC.
Reel/Frame 058586/0240 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
To: CHARLES RIVER LABORATORIES, INC.
Reel/Frame 058652/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: LINNEY, IAN
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 058666/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: WISHART, GRANT
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 058666/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: WARD, STUART
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 058979/0455 →
Continuity (3)
Continuation 17018591 · Sep 11, 2020
Provisional Application 63032070 · May 29, 2020
Provisional Application 62900152 · Sep 13, 2019
Cited By (2)
US 12,252,488 US 12,466,841